MORRISVILLE, N.C. , March 22, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022

- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - Preparing to launch YUTREPIA in late-2022 pending final FDA approval - Company to host webcast and conference call today at 8:30 a.m.

MORRISVILLE, N.C. , March 10, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022 . The company will host a conference call and webcast at 8:30 a.m.

MORRISVILLE, N.C. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022

MORRISVILLE, N.C. , Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022 , with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at

MORRISVILLE, N.C. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director

MORRISVILLE, N.C. , Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman

MORRISVILLE, N.C. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer of Liquidia , will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare

First dry-powder formulation of treprostinil to meet criteria required for FDA approval Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C. , Nov.

-   Increased adoption of generic Treprostinil Injection by patients, physicians and payers -   Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities -   Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C. , Nov.